These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 36059494)

  • 21. Construction of a prognostic risk model for Stomach adenocarcinoma based on endoplasmic reticulum stress genes.
    Li X; Lei Y
    Wien Klin Wochenschr; 2024 Jun; 136(11-12):319-330. PubMed ID: 37993598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
    Liu Z; Sun L; Peng X; Liu S; Zhu Z; Huang C
    Apoptosis; 2023 Dec; 28(11-12):1564-1583. PubMed ID: 37580435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.
    Gao J; Zhao Z; Zhang H; Huang S; Xu M; Pan H
    Cancer Immunol Immunother; 2023 May; 72(5):1121-1138. PubMed ID: 36336725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
    Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z
    Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma.
    Zeng C; Liu Y; He R; Lu X; Dai Y; Qi G; Liu J; Deng J; Lu W; Jin J; Liu Q
    Front Genet; 2022; 13():935056. PubMed ID: 36092903
    [No Abstract]   [Full Text] [Related]  

  • 26. Identification of mitochondrial respiratory chain signature for predicting prognosis and immunotherapy response in stomach adenocarcinoma.
    Yang J; Jin F; Li H; Shen Y; Shi W; Wang L; Zhong L; Wu G; Wu Q; Li Y
    Cancer Cell Int; 2023 Apr; 23(1):69. PubMed ID: 37062830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of RNA methylation-related genes in gastric adenocarcinoma based on bioinformatics.
    He X; Chen X; Yang C; Wang W; Sun H; Wang J; Fu J; Dong H
    PeerJ; 2024; 12():e16951. PubMed ID: 38436027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A ubiquitination-related risk model for predicting the prognosis and immunotherapy response of gastric adenocarcinoma patients.
    Shao S; Sun Y; Zhao D; Tian Y; Yang Y; Luo N
    PeerJ; 2024; 12():e16868. PubMed ID: 38313020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.
    Liu Z; Liu H; Wang Y; Li Z
    BMC Gastroenterol; 2022 Oct; 22(1):435. PubMed ID: 36241983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of an immunogenic cell death prognostic signature for predicting clinical outcome and immune infiltration characterization in stomach adenocarcinoma.
    Liu Y; Zhang L; Lei X; Yin X; Liu S
    Aging (Albany NY); 2023 Oct; 15(20):11389-11411. PubMed ID: 37862109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Constructing a novel mitochondrial-related gene signature for evaluating the tumor immune microenvironment and predicting survival in stomach adenocarcinoma.
    Chang J; Wu H; Wu J; Liu M; Zhang W; Hu Y; Zhang X; Xu J; Li L; Yu P; Zhu J
    J Transl Med; 2023 Mar; 21(1):191. PubMed ID: 36915111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine-Like Protein 1 (CYTL1) as a Key Target of M-Stage Immune Infiltration in Stomach Adenocarcinoma.
    Zhou F; Lin Q; Zheng Z
    Biomed Res Int; 2023; 2023():2926218. PubMed ID: 36825034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a fatty acid metabolism-related gene signature to predict prognosis in stomach adenocarcinoma.
    Liu L; Sun J; Zhong C; Zhang A; Wang G; Chen S; Zhang S; Wang M; Li L
    Aging (Albany NY); 2024 May; 16(10):8552-8571. PubMed ID: 38742949
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of a Prognostic Evaluation Model for Stomach Adenocarcinoma on the Basis of Immune-Related lncRNAs.
    Xu C; Chen Z; Pan X; Liu M; Cheng G; Li J; Mei Y
    Appl Biochem Biotechnol; 2022 Dec; 194(12):6255-6269. PubMed ID: 35904674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Necroptosis-Related lncRNA-Based Signature to Predict Prognosis and Probe Molecular Characteristics of Stomach Adenocarcinoma.
    Luo L; Li L; Liu L; Feng Z; Zeng Q; Shu X; Cao Y; Li Z
    Front Genet; 2022; 13():833928. PubMed ID: 35330731
    [No Abstract]   [Full Text] [Related]  

  • 37. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs.
    Tu H; Zhang Q; Xue L; Bao J
    Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.
    Yuan Q; Zhou Q; Ren J; Wang G; Yin C; Shang D; Xia S
    Cancer Med; 2021 Jun; 10(12):4004-4016. PubMed ID: 33982398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unraveling the unfolded protein response signature: implications for tumor immune microenvironment heterogeneity and clinical prognosis in stomach cancer.
    Ouyang W; Liu Y; Huang H; Tan Y; Huang Z; Jia X; Yu Y; Yao H
    Aging (Albany NY); 2024 May; 16(9):7818-7844. PubMed ID: 38700505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel microRNA signature predicts survival in stomach adenocarcinoma.
    Ding B; Gao X; Li H; Liu L; Hao X
    Oncotarget; 2017 Apr; 8(17):28144-28153. PubMed ID: 28423653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.